Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. - Wikidata - awgldk - TriplyDB

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.

http://www.wikidata.org/entity/Q36984142

about

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Immunotherapy for Alzheimer's disease: hoops and hurdles Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model.Age and apolipoprotein E ε4 effects on neural correlates of odor memory A generic method for design of oligomer-specific antibodies.Ultrasound attacks Alzheimer's disease?Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Biometals and their therapeutic implications in Alzheimer's disease.The therapeutics of Alzheimer's disease: where we stand and where we are heading.Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

P2860

Q26745928-EC049BFE-0CF3-4938-9206-9BA6C2105194 Q26823877-F482BEAC-B776-489C-BDDE-7D9587310800 Q28235248-765340CB-B0B6-490C-8874-6BE02A0F00B0 Q28660580-528C0762-863A-4D3C-9218-F1BEAED73A56 Q30316057-56CEF14C-D605-4108-ABB2-4D0706558926 Q30361851-F62FF0F9-C28D-46A9-89A1-39CD3F37302A Q33624303-64AEDD36-093B-4763-AF71-B790A5701379 Q34043432-33CB87F5-763E-4244-9801-FA2C78E94FF8 Q35117343-E674CFF7-B892-4D43-B5D5-7056A8E17EBE Q35117526-366BE040-FE09-4B9F-81D6-F8831E9C5576 Q36241902-179860E8-0AFE-4ECC-A4E6-A91BFE99295E Q36340365-56AC1E7E-FA41-44DD-A6D7-BFB47EBCD953 Q36484413-0E20B42E-0885-44FF-9AAA-91D40732F933 Q38161675-A4506C10-19D0-4CC5-A5D8-B61065A97D61 Q38176899-C7F70957-5521-4544-877D-877A44D4C819 Q38184618-E890EE0F-45CB-4C0F-800E-6CF8A42D79FF Q38224958-ABA1BFDE-151F-4C7C-BD53-7636426494C3 Q38263669-3F55ECC0-9AEE-4D80-A691-49ED2472E5B8 Q38392585-1C3C4486-2B54-462E-8C13-E30F37057FE6 Q38966308-44EF66F8-EFD5-4B29-8B82-48727C3ABDCD Q40450053-26DD4E67-A003-4A6C-9452-47969FFF8E4E Q46320596-C4AC9F5A-67E8-4F82-982B-4417C1152CF2 Q46348872-1477599C-62B6-4B60-9063-EBF622BEA48B Q53311356-6050E617-2CA4-4877-8465-13F71EA41D0D

P2860

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.

http://www.wikidata.org/entity/Q36984142

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Passive immunization against p ...... ransgenic mice: a pilot study.

@en

type

label

Passive immunization against p ...... ransgenic mice: a pilot study.

@en

prefLabel

Passive immunization against p ...... ransgenic mice: a pilot study.

@en

P1433

Q36984142-EF0F311F-92F0-4839-A72C-F5FD44BD20B8

P1476

Q36984142-110C49CC-A31B-4229-B027-D0AB23D6E39C

P2093

Q36984142-3F1AA0D0-F0ED-4034-A1A6-D450C0FDC725

Q36984142-77589468-902D-47EF-B82F-3E20AD24584F

Q36984142-A216E469-40C0-4A5F-BC40-B0C7ED4C7EC8

Q36984142-B7956B9F-45DF-4268-9087-122EA0B1250F

Q36984142-DB948608-3947-43F1-ABEE-EBAAE469AABB

Q36984142-F96572A6-07D6-47E3-B6B8-8187374CF2DF

P2860

Q36984142-11066D83-0E4D-44B2-A584-39DFFFEC864A

Q36984142-110E8E73-9AC4-486C-B266-E78910CEE0A5

Q36984142-1A66896C-6B70-4E30-9B5C-CCCE8F20E89B

Q36984142-1B2C3100-CDB3-4BF5-880C-DB4E1A82631D

Q36984142-3A36253E-65CA-4F3E-89ED-90E19E5EB51D

Q36984142-3FB1CDCC-4436-4AF5-A487-4736B85E3CB2

Q36984142-4B549D80-E087-451D-9DC4-5D52BC8F4D1F

Q36984142-93568CB3-A555-4AC4-BD12-86E061290201

Q36984142-97E8DFB9-F2D4-4614-9E34-A62B55886395

Q36984142-992392F3-7D76-45E5-B1C7-54F65633F4E6

P304

Q36984142-15EA98AB-4FA5-4836-92C8-E81E7817C003

P31

Q36984142-9E87B38D-103C-4483-9ED6-38831A4A4E2F

P356

Q36984142-FF994FD7-CE27-4A1B-B096-9B0E321DAC60

P433

Q36984142-5D2ADF03-D1AD-438F-AA83-69E2AAB96CBC

P478

Q36984142-A3687353-3CA6-47B2-81D9-4AF9D7D42C92

P577

Q36984142-B9B59CF6-CC18-4E20-A999-57894F09F3D5

P5875

Q36984142-75098412-EF20-42B7-AA55-31BBEFA3AEBE

P698

Q36984142-471913B6-0A96-4C8C-BEA3-F75F2899EB4C

P921

Q36984142-29A5F9FB-1497-407A-BCDC-CCDC70032F1C

Q36984142-D43E14AD-6115-421D-BEE3-11BEAEDE7AFC

P932

Q36984142-924A3D81-4617-444F-A8A2-52F735F2D490

P356

P1433

Neurodegenerative Diseases

P1476

Passive immunization against p ...... ransgenic mice: a pilot study.

@en

P2093

Bin Liu

http://www.w3.org/2001/XMLSchema#string

Cynthia A Lemere

http://www.w3.org/2001/XMLSchema#string

Hans-Ulrich Demuth

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Frost

http://www.w3.org/2001/XMLSchema#string

Martin Kleinschmidt

http://www.w3.org/2001/XMLSchema#string

Stephan Schilling

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer's disease: genes, proteins, and therapy

Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase

Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.

Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis

Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques.

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants.

P304

265-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000335913

http://www.w3.org/2001/XMLSchema#string

P433

1-4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221840635

http://www.w3.org/2001/XMLSchema#string

P698

22343072

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3702016

http://www.w3.org/2001/XMLSchema#string